Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length
8/27/2014 10:38:41 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 12/591,829. The ’829 patent application includes newly allowed claims directed to compositions comprising a double-stranded molecule of between 19 and 52 nucleotides in each strand with various end configurations, including a so-called “3’ overhang” on the antisense strand. As such, the newly allowed patent application broadly covers small interfering RNA, or “siRNA,” molecules of various designs including so-called “dicer substrate” RNAi triggers. Moreover, the claims also cover double-stranded RNAi-mediating molecules with one or more nucleotide analogue such as “unlocked nucleobase analogs,” or “UNAs,” amongst other naturally or non-naturally occurring nucleotide analogues.
Help employers find you! Check out all the jobs and post your resume.
comments powered by